Zhejiang Wenda Pharma Technology Ltd. has identified HER2 (erbB2) and its (exon 20 insertion [Ex20Ins], (Ala775_Gly776insTyrValMetAla)) mutant inhibitors reported to be useful for the treatment of cancer.
Researchers at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have synthesized hydroxyamide derivatives acting as dual lysine-specific histone demethylase 1A (KDM1A, LSD1) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
In a recent publication in Scientific Reports, researchers at City of Hope and collaborators presented a novel CS1 bsAb, called CS1-dbBiTE, conjugating an intact anti-CS1 antibody (elotuzumab) and an anti-human OKT3 antibody at their respective hinge regions using Click chemistry.
Researchers at Boston Children's Hospital and Harvard Medical School have explored the possibility of using anaplastic lymphoma kinase (ALK) as a target for the application of ALK.CAR T cells to treat neuroblastoma, the most common and deadliest tumor of infancy.
Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.
Hangzhou Unogen Biotech Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of lymphoma.
Researchers at Albert-Ludwigs-Universität Freiburg and Deutsches Krebsforschungszentrum (DKFZ) have disclosed drug conjugates comprising fluorescent-labeled dye covalently linked to a radionuclide and a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) acting as positron-emission tomography (PET) and fluorescent imaging agents for diagnosis and treatment of prostate cancer.
CD33 is known to be highly expressed in myeloid cells and a good therapeutic target for treating acute myeloid leukemia (AML). In the search for more potent compounds, researchers from Dragonfly Therapeutics Inc. and Bristol Myers Squibb Inc. investigated the therapeutic potential of BMS-986357, also known as CC-96191.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")